CA3136727A1 - Methods of administering an arip-iprazole injectable preparation - Google Patents

Methods of administering an arip-iprazole injectable preparation Download PDF

Info

Publication number
CA3136727A1
CA3136727A1 CA3136727A CA3136727A CA3136727A1 CA 3136727 A1 CA3136727 A1 CA 3136727A1 CA 3136727 A CA3136727 A CA 3136727A CA 3136727 A CA3136727 A CA 3136727A CA 3136727 A1 CA3136727 A1 CA 3136727A1
Authority
CA
Canada
Prior art keywords
aripiprazole
injectable preparation
salt
patient
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136727A
Other languages
English (en)
French (fr)
Inventor
Matthew HARLIN
Xiaofeng Wang
Yanlin Wang
Arash Raoufinia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3136727(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CA3136727A1 publication Critical patent/CA3136727A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
CA3136727A 2020-04-01 2021-04-01 Methods of administering an arip-iprazole injectable preparation Pending CA3136727A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01
PCT/JP2021/014192 WO2021201238A1 (en) 2020-04-01 2021-04-01 Methods of administering an aripiprazole injectable preparation

Publications (1)

Publication Number Publication Date
CA3136727A1 true CA3136727A1 (en) 2021-10-07

Family

ID=75581573

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3136727A Pending CA3136727A1 (en) 2020-04-01 2021-04-01 Methods of administering an arip-iprazole injectable preparation
CA3163321A Active CA3163321C (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments
CA3212191A Pending CA3212191A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3163321A Active CA3163321C (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments
CA3212191A Pending CA3212191A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Country Status (16)

Country Link
US (5) US20220160621A1 (https=)
EP (3) EP4125903B1 (https=)
JP (4) JP7584535B2 (https=)
KR (3) KR102732030B1 (https=)
CN (3) CN115397420A (https=)
AU (2) AU2021245713A1 (https=)
BR (2) BR112022018647A2 (https=)
CA (3) CA3136727A1 (https=)
ES (1) ES2995466T3 (https=)
HR (1) HRP20241574T1 (https=)
HU (1) HUE069157T2 (https=)
MX (2) MX2022012353A (https=)
PL (1) PL4125903T3 (https=)
TW (3) TWI865760B (https=)
WO (2) WO2021201238A1 (https=)
ZA (1) ZA202210633B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法
US20250387321A1 (en) 2023-03-17 2025-12-25 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
AU2024263986A1 (en) * 2023-04-26 2025-10-09 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
MX2009014115A (es) 2007-06-25 2010-04-21 Otsuka Pharma Co Ltd Microesferas que tienen estructura de nucleo/corteza.
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
JP2020520380A (ja) * 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法

Also Published As

Publication number Publication date
KR20220161403A (ko) 2022-12-06
HRP20241574T1 (hr) 2025-01-31
EP3941470A1 (en) 2022-01-26
CN119792290A (zh) 2025-04-11
TW202200141A (zh) 2022-01-01
EP4467194A3 (en) 2025-01-08
US20240374506A1 (en) 2024-11-14
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
JP7733000B2 (ja) 2025-09-02
MX2022012353A (es) 2022-10-31
JP2023520004A (ja) 2023-05-15
AU2021248212A1 (en) 2022-12-01
KR20240165486A (ko) 2024-11-22
WO2021201239A1 (en) 2021-10-07
KR20220161402A (ko) 2022-12-06
KR102732030B1 (ko) 2024-11-20
JP7584535B2 (ja) 2024-11-15
US20260034053A1 (en) 2026-02-05
AU2021245713A1 (en) 2022-12-01
MX2022012354A (es) 2022-10-31
US20230129919A1 (en) 2023-04-27
US20220160621A1 (en) 2022-05-26
CN115379842A (zh) 2022-11-22
BR112022018647A2 (pt) 2022-11-08
HUE069157T2 (hu) 2025-02-28
JP2025020306A (ja) 2025-02-12
CA3163321A1 (en) 2021-10-07
BR112022018721A2 (pt) 2022-11-01
EP4125903B1 (en) 2024-10-09
EP4125903A1 (en) 2023-02-08
EP4467194A2 (en) 2024-11-27
TWI865760B (zh) 2024-12-11
TW202523329A (zh) 2025-06-16
WO2021201238A1 (en) 2021-10-07
EP4125903C0 (en) 2024-10-09
US20230225962A1 (en) 2023-07-20
CN115397420A (zh) 2022-11-25
CA3163321C (en) 2023-12-19
JP2023519425A (ja) 2023-05-10
JP2025176037A (ja) 2025-12-03
PL4125903T3 (pl) 2025-02-03
ES2995466T3 (en) 2025-02-10
TWI906279B (zh) 2025-12-01
CA3212191A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20230225962A1 (en) Methods of administering an aripiprazole injectable preparation
JP5683810B2 (ja) メトトレキセート濃厚溶液
US12016951B2 (en) Edaravone pharmaceutical composition
JP5872551B2 (ja) パラセタモールを含む医薬組成物およびその製造法
US20260115131A1 (en) Methods of administering an aripiprazole injectable preparation
AU2011273064A1 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
WO2014210369A2 (en) Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
US20250017902A1 (en) Pharmaceutical composition for treating migraine
KR20100124860A (ko) 독소필린을 포함하는 변형 방출 조성물
HK40077871A (en) Methods of administering an aripiprazole injectable preparation
WO2019191200A1 (en) Method and formulation for producing anesthesia of internal aspect of eye wall by topical application
US20170165210A1 (en) Pharmaceutical Compositions Comprising Paracetamol and Process for Preparing The Same
HK40063844B (zh) 一种药物组合物及其应用
WO2017023361A1 (en) Pharmaceutical composition comprising sumatripan for treating migraine
HK40081123A (en) Methods for dose initiation of aripiprazole treatments
HK40081123B (en) Methods for dose initiation of aripiprazole treatments

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211012

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20241030

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250227

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250227

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250506

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250506

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250506

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250924

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20260116

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260121

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260226